Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations

NCT07279402 is registered in ClinicalTrials.gov with Antalya Training and Research Hospital as lead sponsor.

NCT NCT07279402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07279402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations
Lead sponsor
Antalya Training and Research Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 15, 2025
Completion date
October 1, 2027
Enrollment
150 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

atezolizumab, nsclc stage iv, pd-l1 gene mutation, real world study